Entinostat reprogrammed tumor-infiltrating MDSCs by significantly inhibiting the expression of ARG1, iNOS and COX2 and suppressing the function of immunosuppressive MDSCs, thereby overcoming immune resistance [183, 184]. Here, NOS2 is linked to neoplasm.